Eisai (4523) Stock Price, Fundamentals & Analysis

What 4523 does

Eisai (4523) is a stock listed on the Tokyo Stock Exchange stocks and operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Headquartered in Tokyo, Japan, the company researches, develops, manufactures, and sells pharmaceuticals. Its products include Lenvima, a multi-kinase inhibitor involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. Eisai also provides prescription and over-the-counter drugs, with a focus on neurology and oncology, and operates across Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally.

Key numbers explained

• The current price of 4,955 JPY reflects the latest trading value of one share.
• The trailing P/E ratio of 36.2 shows how much investors pay per unit of earnings per share the company has already earned over the last 12 months.
• The forward P/E ratio of 24.5 uses expected earnings to show a more future-looking valuation.
• The dividend yield of 3.23% is the annual dividend as a percentage of the current share price.
• The ex-dividend date of Sep 29, 2026 is the cutoff to own the stock and receive the next dividend payment.
• 117% of earnings paid out as dividends means the company distributes more than it earns in the trailing period.
• The beta of -0.05 suggests the stock's price movement has a very weak inverse relationship to the overall market.
• The 52-week range of 3,660 – 5,243 JPY shows the lowest and highest price seen in the past year.

What to watch

Eisai's performance is tied to the broader Healthcare sector and the Japanese pharmaceutical industry. Investors often compare it with peers such as Shionogi (4507), Astellas (4503), and Chugai Pharmaceutical (4519), which also trade on the Tokyo Stock Exchange. The company's pipeline in neurology and oncology, along with its product approvals and regulatory developments, can influence its outlook. Revenue growth of 15.6% year over year and a profitMargin of 4.9% are useful indicators of operational momentum and cost control. The next earnings report is scheduled for Nov 10, 2026, which typically brings updated guidance and management commentary.